Last SFr.185.00 CHF
Change Today +4.00 / 2.21%
Volume 61.6K
As of 11:43 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cosmo pharmaceuticals spa (COPN) Snapshot

Open
SFr.182.20
Previous Close
SFr.181.00
Day High
SFr.186.70
Day Low
SFr.181.00
52 Week High
07/9/14 - SFr.193.70
52 Week Low
09/20/13 - SFr.59.00
Market Cap
2.8B
Average Volume 10 Days
39.6K
EPS TTM
SFr.4.88
Shares Outstanding
15.0M
EX-Date
04/28/14
P/E TM
31.2x
Dividend
SFr.1.00
Dividend Yield
0.66%
Current Stock Chart for COSMO PHARMACEUTICALS SPA (COPN)

Related News

No related news articles were found.

cosmo pharmaceuticals spa (COPN) Related Businessweek News

No Related Businessweek News Found

cosmo pharmaceuticals spa (COPN) Details

Cosmo Pharmaceuticals S.p.A. operates as a specialty pharmaceutical company primarily in Italy. The company develops, licenses, and commercializes proprietary pharmaceutical products, primarily for the treatment of inflammatory bowel diseases, colon infections, and other colon diseases, as well as topically treated skin disorders; and manufactures pharmaceutical products for third parties and provides related services. Its products comprise Lialda, Mezavant, and Mesavancol proprietary formulations for mild to moderate ulcerative colitis; Zacol NMX for intestinal disorders; Uceris and Cortiment products for ulcerative colitis; and Low Molecular Weight Heparin MMX for the treatment of Ulcerative Colitis. The company also develops various products, including Rifamycin SV MMX, which is under Phase III clinical trials and is intended for use as an antibiotic; CB-03-01, a steroidal ester, androgen antagonist that is under Phase II clinical trials; CB-17-01, a coloring agent that is used to stain the mucosa to discover pre-cancerous lesions and polyps in the colon and has completed Phase II clinical trials; and CB-01-16, which is under Phase I clinical trials and is intended for the treatment of opioid induced constipation. It has a strategic collaboration agreement with Santarus Inc. The company is headquartered in Lainate, Italy.

163 Employees
Last Reported Date: 03/27/14

cosmo pharmaceuticals spa (COPN) Top Compensated Officers

Founder and Chairman
Total Annual Compensation: €750.0K
Chief Financial Officer, Head of Investor Rel...
Total Annual Compensation: €328.5K
Compensation as of Fiscal Year 2013.

cosmo pharmaceuticals spa (COPN) Key Developments

Cosmo Pharmaceuticals S.p.A. - Analyst/Investor Day

To discuss in its definitive merger agreement with Cosmo Technologies Limited

Cosmo Pharmaceuticals S.p.A. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 03:30 PM

Cosmo Pharmaceuticals S.p.A. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 03:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Alessandro E. Della Chà, Chief Executive Officer and Director, Chris Tanner, CFO.

Cosmo Pharmaceuticals S.p.A. Announces Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Earnings Guidance for the Fiscal Year 2014

Cosmo Pharmaceuticals S.p.A. announced consolidated earnings results for the year ended December 31, 2013. For the year, revenues were EUR 56.4 million against EUR 59.5 million a year ago. Profit before taxes was EUR 71.7 million against EUR 26.9 million a year ago. Net profit was EUR 68.7 million against EUR 19.3 million a year ago. Profit per share was EUR 4.81 against EUR 1.41 a year ago. The company expects to post a substantial increase both in operating revenues to approx. EUR 100 million and strong growth in operating profits as well as net income in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COPN:SW SFr.185.00 CHF +4.00

COPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $48.38 USD +0.58
Depomed Inc $12.96 USD -0.44
Durect Corp $1.61 USD +0.02
Supernus Pharmaceuticals Inc $10.52 USD -0.12
Veloxis Pharmaceuticals A/S kr1.97 DKK +0.10
View Industry Companies
 

Industry Analysis

COPN

Industry Average

Valuation COPN Industry Range
Price/Earnings 31.4x
Price/Sales 38.3x
Price/Book 10.2x
Price/Cash Flow 32.9x
TEV/Sales 36.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COSMO PHARMACEUTICALS SPA, please visit www.cosmopharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.